NEW YORK - Tiziana Life Sciences Ltd (NASDAQ:TLSA), a biotechnology firm, has announced positive clinical results from its Expanded Access Program (EAP) for patients with non-active secondary progressive multiple sclerosis (na-SPMS).
According to the company's recent press release, 70% of the participants experienced an improvement in fatigue after six months of follow-up, a significant symptom of multiple sclerosis (MS) measured by the Modified Fatigue Impact Scale (MFIS).
The study involved 10 patients who had previously experienced disease progression while on ocrelizumab treatment. These patients received intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as part of the EAP. Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School, noted that all patients either stabilized or improved in key clinical measures, with seven showing clinically meaningful improvement in fatigue.
In addition to fatigue, the clinical outcome measures included the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk Test (T25WT), and Pyramidal Scores. These measures are critical in evaluating the physical function of MS patients, who typically experience a decline in function over time.
Foralumab is designed to modulate T cell function and reduce inflammation, which has been shown to have therapeutic effects in patients with COVID-19, MS, and in healthy subjects. Tiziana Life Sciences has emphasized the potential of foralumab to address the unmet needs of individuals living with MS, particularly in managing fatigue, which can severely affect daily life.
The company's approach to drug delivery, focusing on nasal administration, aims to improve efficacy and safety compared to intravenous delivery. While the findings are promising, they are based on a small sample size, and further research is necessary to validate these results.
This announcement is based on a press release statement and does not constitute an endorsement of Tiziana Life Sciences or its products. The company's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements.
InvestingPro Insights
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has recently shared encouraging clinical outcomes, which may have a significant impact on the company's future prospects. To better understand the financial context of these developments, let's delve into some key metrics and insights from InvestingPro.
InvestingPro Data highlights that TLSA currently holds a market capitalization of $66.81 million. This is a critical figure for investors as it reflects the company's size and market value. Moreover, the Price/Book ratio as of the last twelve months ending Q2 2023 stands at 5.04, indicating how the market values the company's net assets.
Another metric to consider is the 1 Month Price Total Return, which has been substantial at 43.23%, showcasing a strong short-term performance in the market.
Two InvestingPro Tips that may be particularly relevant for investors considering TLSA are:
1. The company has been actively buying back shares, which could be a sign of management's confidence in the future of the company and its valuation.
2. TLSA holds more cash than debt on its balance sheet, providing a solid liquidity position that could support future research and development activities, especially important for a biotech firm like Tiziana Life Sciences.
For investors interested in a more comprehensive analysis, there are 10 additional InvestingPro Tips available on the InvestingPro platform, which can be accessed at https://www.investing.com/pro/TLSA. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
These financial insights, combined with the recent clinical results, may provide a more complete picture of Tiziana Life Sciences Ltd's potential for growth and stability in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.